Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

AYTU

Aytu BioPharma Inc

Jun 14 • 04:00PM ET

2.85

Dollar change -0.02
Percentage change -0.70	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VXF DFAT DFAC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.64	Insider Own	3.80%	Shs Outstand	5.52M	Perf Week	-5.94%
Market Cap	15.87M	Forward P/E	3.70	EPS next Y	0.77	Insider Trans	0.00%	Shs Float	5.36M	Perf Month	-6.86%
Income	-13.68M	PEG	-	EPS next Q	-0.45	Inst Own	32.27%	Short Float	8.64%	Perf Quarter	-0.70%
Sales	93.76M	P/S	0.17	EPS this Y	51.27%	Inst Trans	-	Short Ratio	22.62	Perf Half Y	7.55%
Book/sh	5.53	P/B	0.52	EPS next Y	130.92%	ROA	-9.91%	Short Interest	0.46M	Perf Year	62.86%
Cash/sh	3.55	P/C	0.80	EPS next 5Y	-	ROE	-38.18%	52W Range	1.38 - 3.50	Perf YTD	0.35%
Dividend Est.	-	P/FCF	1.83	EPS past 5Y	72.18%	ROI	-37.42%	52W High	-18.57%	Beta	-1.42
Dividend TTM	-	Quick Ratio	0.69	Sales past 5Y	114.68%	Gross Margin	59.88%	52W Low	106.52%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	0.85	EPS Y/Y TTM	95.63%	Oper. Margin	1.55%	RSI (14)	38.01	Volatility	5.25% 5.16%
Employees	150	Debt/Eq	1.03	Sales Y/Y TTM	-9.95%	Profit Margin	-14.60%	Recom	1.00	Target Price	8.00
Option/Short	No / Yes	LT Debt/Eq	0.19	EPS Q/Q	73.00%	Payout	-	Rel Volume	1.61	Prev Close	2.87
Sales Surprise	3.73%	EPS Surprise	18.75%	Sales Q/Q	-20.85%	Earnings	May 15 AMC	Avg Volume	20.48K	Price	2.85
SMA20	-7.82%	SMA50	-6.35%	SMA200	3.72%	Trades		Volume	33,068	Change	-0.70%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-30-21	Initiated	Cantor Fitzgerald	Overweight	$11
May-29-20	Initiated	H.C. Wainwright	Buy	$3

May-29-24 06:44PM	Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024 (Newsfile)
May-23-24 09:00AM	Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 (ACCESSWIRE)
May-16-24 09:53AM	Q3 2024 Aytu Biopharma Inc Earnings Call (Thomson Reuters StreetEvents)
03:07AM	Aytu BioPharma Inc (AYTU) Q3 2024 Earnings Call Transcript Highlights: Strategic Gains Amidst ... (GuruFocus.com)
May-15-24 08:54PM	AYTU Stock Earnings: Aytu BioPharma Beats EPS, Beats Revenue for Q3 2024 (InvestorPlace) -7.83%
04:05PM	Loading…
04:05PM	Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results (ACCESSWIRE)
May-08-24 04:15PM	Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024 (ACCESSWIRE)
Apr-03-24 09:00AM	Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024 (ACCESSWIRE)
07:00AM	Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now (GlobeNewswire)
Apr-02-24 07:00AM	Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now (GlobeNewswire)
Feb-16-24 08:27AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Call Transcript (Insider Monkey)
Feb-15-24 05:49AM	Q2 2024 Aytu Biopharma Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-14-24 04:05PM	Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter (ACCESSWIRE) +5.35%
Feb-07-24 04:15PM	Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024 (ACCESSWIRE)
Jan-23-24 09:00AM	Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 (ACCESSWIRE)
07:00AM	Loading…
Dec-06-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now (GlobeNewswire)
Dec-05-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now (GlobeNewswire)
Nov-30-23 08:00AM	Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023 (ACCESSWIRE)
Nov-15-23 09:44AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call Transcript (Insider Monkey) -22.11%
Nov-14-23 04:05PM	Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results (ACCESSWIRE) +10.11%
Nov-08-23 08:30AM	Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year (ACCESSWIRE)
Nov-07-23 04:15PM	Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023 (ACCESSWIRE) +5.14%
Oct-26-23 08:00AM	Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement (ACCESSWIRE) +5.82%
Oct-09-23 04:15PM	Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023 (ACCESSWIRE)
Sep-28-23 08:18AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2023 Earnings Call Transcript (Insider Monkey) +39.06%
Sep-27-23 04:20PM	Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023 (ACCESSWIRE) +16.36%
Sep-21-23 08:25PM	Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023 (ACCESSWIRE)
Sep-13-23 08:00AM	Aytu BioPharma to Present at LD Micro Main Event XVI Conference (ACCESSWIRE)
Aug-09-23 10:26AM	UPS downgraded, Eli Lilly upgraded: Wall Street's top analyst calls (The Fly) +10.30%
07:43AM	Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Expected To Breakeven In The Medium-Term (Simply Wall St.)
09:15AM	Loading…
Aug-08-23 09:15AM	Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline (Newsfile)
Jul-31-23 08:00AM	Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority (ACCESSWIRE)
Jul-10-23 08:00AM	Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement (ACCESSWIRE) +5.36%
Jun-14-23 08:00AM	Aytu to Participate in the Maxim Group Virtual Healthcare Conference (ACCESSWIRE)
Jun-13-23 01:45PM	Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market (ACCESSWIRE) +6.59%
Jun-09-23 08:00AM	Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director (ACCESSWIRE)
May-16-23 11:51AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2023 Earnings Call Transcript (Insider Monkey)
May-11-23 04:25PM	AYTU Stock Earnings: Aytu Misses EPS, Revenue Estimates (InvestorPlace)
04:05PM	Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results (ACCESSWIRE)
May-04-23 04:30PM	Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023 (ACCESSWIRE)
May-01-23 08:00AM	Aytu BioPharma Subleases a Portion of Its Manufacturing Facility (ACCESSWIRE)
Apr-27-23 08:00AM	Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer (ACCESSWIRE)
Mar-06-23 09:55AM	Aytu BioPharma Inc. (AYTU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Feb-23-23 04:33PM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2023 Earnings Call Transcript (Insider Monkey) -5.78%
Feb-21-23 04:10PM	Aytu BioPharma Reports Second Quarter of Fiscal Year 2023 (ACCESSWIRE)
03:00PM	Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023 (ACCESSWIRE)
Feb-14-23 08:00AM	Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results (ACCESSWIRE)
Feb-07-23 08:00AM	Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023 (ACCESSWIRE)
Feb-06-23 10:57AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Jan-25-23 08:00AM	Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance (ACCESSWIRE) -6.46%
Jan-24-23 08:00AM	Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31 (ACCESSWIRE)
Jan-10-23 08:00AM	Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients (ACCESSWIRE)
Jan-05-23 04:01PM	Aytu BioPharma Announces 1-for-20 Reverse Stock Split (ACCESSWIRE) +7.28%
Dec-29-22 06:01AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2023 Earnings Call Transcript (Insider Monkey)
Nov-30-22 08:00AM	Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect (ACCESSWIRE)
Nov-22-22 04:05PM	Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule (ACCESSWIRE)
Nov-17-22 08:58AM	US$5.50: That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After Its Latest Results (Simply Wall St.)
08:00AM	Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row (ACCESSWIRE)
Nov-16-22 08:00AM	Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso (ACCESSWIRE) +12.58%
05:59AM	Aytu BioPharma First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
Nov-14-22 04:05PM	Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023 (ACCESSWIRE)
Nov-07-22 04:01PM	Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022 (ACCESSWIRE)
Oct-25-22 08:00AM	Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company's Term Loan (ACCESSWIRE) +6.72%
Oct-13-22 10:57AM	Aytu BioPharma Announces Strategic Shift, Indefinite Suspension of Clinical Development Programs (Benzinga)
08:00AM	Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs (ACCESSWIRE)
Oct-05-22 08:00AM	Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT(R) in Response to Reported Generic Adderall(R) XR Supply Disruptions (ACCESSWIRE) -5.18%
Sep-27-22 04:30PM	Edited Transcript of AYTU.OQ earnings conference call or presentation 27-Sep-22 8:30pm GMT (Thomson Reuters StreetEvents)
04:05PM	Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue (ACCESSWIRE)
Sep-20-22 08:00AM	Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022 (ACCESSWIRE)
Sep-14-22 08:00AM	Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin (ACCESSWIRE)
Aug-24-22 08:00AM	Aytu BioPharma to Participate in September 2022 Investor Conferences (ACCESSWIRE)
Aug-16-22 08:00AM	Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin (ACCESSWIRE)
Aug-15-22 04:01PM	Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering (ACCESSWIRE)
Aug-09-22 09:15AM	Aytu BioPharma Announces Pricing of Public Offering (ACCESSWIRE) -51.67%
Aug-08-22 04:01PM	Aytu BioPharma Announces Launch of Public Offering (ACCESSWIRE)
Jul-26-22 08:00AM	Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference (ACCESSWIRE) -6.48%
Jul-20-22 08:00AM	Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome (ACCESSWIRE)
Jun-29-22 08:00AM	Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors (ACCESSWIRE)
Jun-13-22 08:00AM	Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference (ACCESSWIRE) -8.65%
May-17-22 07:29AM	Aytu BioPharma Plans To Divest / Discontinue Non Core Assets (Benzinga) +13.05%
May-16-22 04:02PM	Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities (ACCESSWIRE) -5.85%
Apr-25-22 08:00AM	Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology (ACCESSWIRE)
Apr-19-22 08:00AM	Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome (ACCESSWIRE) -12.68%
Mar-23-22 08:00AM	Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R) (ACCESSWIRE)
Mar-22-22 08:00AM	Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit (ACCESSWIRE)
Mar-08-22 08:00AM	Aytu BioPharma to Participate in the 34th Annual Roth Conference (ACCESSWIRE)
Mar-07-22 04:05PM	Aytu BioPharma Announces Closing of $7.6 Million Registered Offering (ACCESSWIRE)
Mar-02-22 08:00PM	Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering (ACCESSWIRE) +5.74%
08:00AM	Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome (ACCESSWIRE)
Feb-18-22 09:40AM	Has Aytu BioPharma Inc. (AYTU) Outpaced Other Medical Stocks This Year? (Zacks)
Feb-14-22 04:05PM	Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results (ACCESSWIRE)
Jan-31-22 08:00AM	Aytu BioPharma Completes $15 Million Debt Refinancing (ACCESSWIRE) +13.91%
Jan-04-22 08:00AM	Aytu BioPharma Appoints Mark Oki as Chief Financial Officer (ACCESSWIRE)
Jan-03-22 08:00AM	Aytu BioPharma to Present at H.C. Wainwright BioConnect Conference (ACCESSWIRE) +14.81%
Dec-14-21 09:30AM	Denovo Biopharma LLC Announces Partner Aytu BioPharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-Danlos Syndrome (PR Newswire)
Dec-13-21 08:00AM	Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome (ACCESSWIRE)
Dec-09-21 11:38AM	Aytu BioPharma's (AYTU) AR101 Gets FDA's Orphan Drug Status (Zacks)
Dec-08-21 08:00AM	Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome (ACCESSWIRE) -8.37%
Nov-23-21 08:00AM	Aytu BioPharma Announces Issuance of First U.S. Patent Supporting Healight Ultraviolet-A Respiratory Catheter (ACCESSWIRE)
Nov-17-21 08:00AM	Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500(TM) (ACCESSWIRE)

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PYSZCZYMUKA GREG	Chief Commerical Officer	Jun 16 '23	Buy	1.87	12,000	22,428	21,935	Jun 20 08:35 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AYTU

Aytu BioPharma Inc

Upgrade your FINVIZ experience